Drug intelligence / Profile preview

AZD0530 + carboplatin + paclitaxel

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of AZD0530 (saracatinib), carboplatin, and paclitaxel. **AZD0530 (saracatinib)** is an orally available dual kinase inhibitor that selectively inhibits Src family kinases and Bcr-Abl tyrosine kinase. It is being developed primarily by AstraZeneca. *Carboplatin* is a platinum-based chemotherapeutic agent that forms DNA crosslinks, interfering with DNA repair and replication. *Paclitaxel* is a microtubule-stabilizing agent that inhibits cell division. The combination is being explored for the treatment of advanced ovarian cancer, aiming to enhance standard chemotherapy efficacy by targeting complementary oncogenic pathways: Src family kinases (cell survival, migration), DNA structure (crosslinking), and microtubule dynamics (mitosis inhibition)[3][4][6][7][8].

Other names: saracatinib + carboplatin + paclitaxel

Targets

SFK (SRC family kinases)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)

Beyond the preview

Go deeper on AZD0530 + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD0530 + carboplatin + paclitaxel.

Explore the full profile